title: Chemical kinomics - a target gene family approach in chemical biology.
abstract: Traditionally, protein kinases have been regarded as non-druggable targets, instead they play a central role in physiological and pathophysiological processes. This changed when STI571, an inhibitor of the Bcr-Abl kinase, known as Gleevec, reached the market as the first designer drug. Ever since, kinase-directed research and development (R&D) expanded rapidly, leading to more than 45 clinically relevant kinase inhibitors. At a comparable pace the kinase-based technologies matured, cumulating in the development of sophisticated chemogenetic and chemoproteomic tools, which are referred to as chemical kinomics.:
authors: Axxima Pharmaceuticals AG, Max-Lebsche-Platz 32, 81377, Munich, Germany. Electronic address:bert.klebl@axxima.com.
authors: Bert M
authors: BM
authors: Klebl